Connect with us

Health

Russia Partners India, South Korea to Produce Vaccines

Published

on

RDIF CEO Kirill Dmitriev Russia

By Kester Kenn Klomegah

With a strong structured plan and that includes President Vladimir Putin weekly meetings with regional governors and related ministry officials, Russia is making headway in mobilising first its own domestic resources in fighting and controlling the coronavirus pandemic.

Under these time-testing conditions, the Russian government also ponders on the necessity to adopt a concerted approach to the economic sectors related to the public health system, making efforts to strengthen fundamental research in all health disciplines and close the pitfalls in its policy.

Arguably, Russia is really moving with innovative orientations, exploring to find lasting solutions. Without doubts, Russia is far ahead, both in terms of medical tests and vaccines. Currently, it is partnering with India and South Korea in manufacturing vaccines for the immunization of both foreigners and Russians.

“India and South Korea are already producing the vaccine, and many of these enterprises will reach full capacity in April. Thus, this is truly the greatest achievement of Russian science, which is widely acknowledged by the entire world,” CEO of the Russian Direct Investment Fund (RDIF) Kirill Dmitriev told Russian President Vladimir Putin during an early April meeting to review developments as well as production and promotion of Russian vaccines.

In addition, he informed the president that RDIF and its partners are actively working with Russian manufacturers, it took three months to build Sputnik Technopolis, one of the largest plants to produce the vaccine, and together with R-Pharm. Russia is setting up international production per agreements with 10 countries and 20 manufacturers, including the world’s largest producers.

Beyond that, the Russian Direct Investment Fund is actively implementing a programme, of course, with a focus on vaccinating Russian citizens, but part of the vaccine produced abroad will simultaneously be delivered to foreign markets, according to Dmitriev.

According to his assessment, Russia is not only one of the current leaders in the world in terms of vaccination rate, but it can provide vaccines to all people in Russia who want to be vaccinated before June using the production capacities in Russia and abroad.

“As I understood from talking to experts, our vaccine is effective against all known strains of the virus,” Putin commented during the discussion, and Kirill Dmitriev smartly added that “due to the two jabs, it is better than the other vaccines as relates to mutations. We believe that our vaccine is one of the best in the world, including against new strains of COVID-19.”

Reports show that Russia has produced 20.1 million doses of the Sputnik V vaccine as of March 17, while 4.3 million people, out of a population of 144 million, have received both shots of the vaccine.

According to data from Johns Hopkins University, at 225,572, the total coronavirus-related death toll places Russia third after the United States, which has reported over 553,000 deaths, and Brazil, with over 325,000.

According to the Russian Statistics Service, this April Russia has recorded over 225,000 deaths related to coronavirus since the start of the pandemic. That Russia has the third-highest death toll in the world.

The Russian Direct Investment Fund (RDIF) is Russia’s sovereign wealth fund established in 2011 by the Russian government to make investments in leading companies of high-growth sectors of the Russian economy. Its mandate is to co-invest alongside the world’s largest institutional investors – direct investment funds, sovereign wealth funds and leading companies.

Health

Helical Secures $10m Funding Package for Expansion

Published

on

Helical

By Dipo Olowookere

A $10 million capital has been raised by Helical to support expansion across more top-20 pharma programmes and growth of its deployed science engineering team.

The firm will also use the money to build the compounding evidence layer that improves performance across diseases, as its mission is to make every scientist able to test hypotheses at the speed of inference and to turn in-silico discovery into a reliable engine for R&D throughput.

The funding package was from redalpine, Gradient, BoxGroup, Frst and notable angels, including Aidan Gomez (CEO Cohere), Clement Delangue (CEO HuggingFace) and Mario Goetze (pro soccer player).

Helical has a product known as the virtual AI lab for pharma, an application layer that turns biological foundation models into decision-ready, reproducible in-silico discovery workflows.

The platform has two product surfaces — the Virtual Lab for biologists and translational scientists, and the Model Factory for ML engineers and data scientists — built on the same data, the same models, and the same results.

By putting both sides in the same system, Helical closes the gap between computational predictions and biological decision-making, so teams that traditionally worked in silos can collaborate on the same evidence.

Helical was founded in early 2024. It was created by three school friends who took different paths to the same problem.

Rick Schneider built tech at Amazon and later helped the German enterprise Celonis scale in France and Japan. Maxime Allard led data science teams at IBM before pursuing a PhD focused on reinforcement learning and robotics. Mathieu Klop became a cardiologist and genomics researcher.

When bio foundation models emerged, the trio saw the chance to build the missing application layer that would let pharma teams move from model experimentation to reproducible, production discovery.

“The models alone don’t discover drugs. The system does. Pharma teams need a system that turns foundation models into workflows scientists can run, validate, and defend.

“We built Helical to make in-silico science reproducible at pharma scale, so teams can go from hypothesis to decision in days instead of months,” the co-founder of Helical, Mr Rick Schneider, said.

“We are at a unique point in time where biological foundation models and general language reasoning models are converging.

“We backed Helical because we strongly believe they have what it takes to build the pharma AI orchestration platform that will drive this transition from siloed AI models to integrated virtual AI labs,” the General Partner at redalpine, Mr Daniel Graf, stated.

Continue Reading

Health

NARD Suspends Indefinite Strike, Gives FG Fresh Two-Week Ultimatum

Published

on

resident doctors strike

By Adedapo Adesanya

The Nigerian Association of Resident Doctors (NARD) has suspended its planned nationwide indefinite strike, granting the federal government a two-week ultimatum to address lingering welfare issues affecting resident doctors across the country.

The decision was taken after an emergency meeting of the association’s National Executive Council on Tuesday, where members reviewed assurances from government representatives and resolved to give dialogue another chance.

NARD said the suspension was informed by “progress made” in negotiations, particularly commitments on the prompt payment of salary arrears, hazard allowances, and steps toward resolving issues surrounding the Medical Residency Training Fund.

The association did not declare a full resolution of the dispute. It noted that the government had shown “renewed willingness” to address the concerns that triggered the strike threat.

The association noted that while these engagements signalled a willingness by the government to resolve the dispute, several critical issues remain outstanding, particularly the delayed payment of promotion arrears, salary arrears, the 2026 Medical Residency Training Fund (MRTF), and the backlog of 19 months’ professional allowance arrears owed to resident doctors.

It also expressed concern over the Federal Government’s decision to halt the implementation of the reviewed PAT, which had earlier triggered widespread dissatisfaction among its members and raised fears of disruption to healthcare services nationwide.

Despite these unresolved issues, NARD said it opted to suspend the strike as a demonstration of goodwill and commitment to ongoing dialogue, while giving the government a two-week window to take concrete, measurable and verifiable steps to meet its demands.

The association insisted on the immediate reversal of the decision affecting the PAT, payment of all outstanding arrears, prompt disbursement of the MRTF, and full settlement of the accumulated professional allowance backlog.

It warned that it would reconvene at the expiration of the ultimatum to assess the level of compliance and determine its next course of action, adding that failure by the government to meet its demands within the stipulated timeframe would result in the resumption of the suspended strike without further notice.

NARD also called on its members nationwide to remain calm, united and resolute, while urging the Federal Government to act swiftly to prevent a potential crisis in the health sector.

The association further appreciated the interventions of the Vice President and other stakeholders, expressing hope that their involvement would lead to the timely resolution of the dispute and help sustain healthcare delivery across the country.

Continue Reading

Health

Jacaranda Gets Funds to Expand Affordable Maternal Healthcare in Kenya

Published

on

Jacaranda Maternity

By Modupe Gbadeyanka

To expand affordable healthcare in Kenya, Swedfund has invested about $600,000 into Jacaranda Health Limited (Jacaranda Maternity) to support innovations in neonatal intensive care and strengthen Jacaranda’s ability to provide life-saving services to underserved populations.

Jacaranda Maternity provides high-quality maternal health care at more affordable pricing than typical private providers, focusing on women in Nairobi’s low- and middle-income communities.

The new funding will support the opening of new hospitals, upgrading of neonatal care, and improvements to existing facilities.

Maternal and newborn health outcomes in Kenya remain a challenge, with maternal mortality still high despite improvements in skilled birth attendance.

Public health facilities play a central role but face capacity constraints, while access to reliable, quality care varies across regions and income groups.

Private healthcare providers offering essential maternity services at accessible price points can complement public provision.

Jacaranda Maternity aims to expand its network to six hospitals to achieve financial sustainability while scaling its impact. The healthcare provider is a recognised leader in promoting women’s health, with 71 percent of its staff being women, and a track record of effective environmental and social management.

“This investment will help Jacaranda Maternity provide life-saving care to more women and families while furthering Swedfund’s mission to promote inclusive and sustainable healthcare,” a Senior Investment Manager at Swedfund, Audrey Obara, said.

Continue Reading

Trending